| Wissenschaftl. Titel | A Phase II, open-label, multicenter, randomized study evaluating the efficacy and safety of adjuvant autogene cevumeran (plus atezolizumab and mFOLFIRINOX versus mFOLFIRINOX alone) in patients with resected PDAC who have not received prior systemic anticancer treatment for PDAC and have no evidence of disease after surgery |
| Erkrankung |
Verdauung:
Bauchspeicheldrüsenkrebs (Pankreaskarzinom):
adjuvant
|
| weitere Prüfzentren | |
| Kurzprotokoll | Kurzprotokoll |
| Links | Zu den Ein- und Ausschlusskriterien |
erstellt 17.09.2024 Admin02
geändert 18.09.2024 Admin07